Predictive Modelling of 6-Fluoro-3-Hydroxy-2-Pyrazine Carboxamide Drug Delivery Efficacy in Pegylated Bionanocomposite Through First Principles Simulation

Author:

Adekoya Oluwasegun Chijioke1,Adekoya Gbolahan Joseph1,Liu Wanjun2,Sadiku Emmanuel Rotimi1,Hamam Yskandar1

Affiliation:

1. Tshwane University of Technology

2. Donghua University

Abstract

Abstract

This research investigates the drug delivery efficacy for 6-fluoro-3-hydroxy-2-pyrazinecarboxamide (Favipiravir) in PEGylated bionanocomposites using a predictive modelling approach. The study focuses on understanding the interaction mechanisms between Favipiravir (FAV) and polyethylene glycol (PEG)/graphene oxide (GO) (GO/PEG) nanosheets, across various environmental conditions. To evaluate drug delivery efficacy, the following key parameters were calculated: adsorption energies ranging from-202.61 to -3.46 kcal/mol indicating the strength of binding between the drug and nanocarrier; net charge transfer values between -0.222 to 0.373 electrons, reflecting the degree of charge migration; release times spanning a wide range from 3.4×10−14 to 2.38×10132 ms, which impacts the drug release kinetics; and thermodynamic parameters such as changes in Gibbs free energy (ΔG) between 183.34 and 16.95 kcal/mol, and changes in enthalpy (ΔH) between -203.64 and 0.55 kcal/mol, providing insights into the favorability and spontaneity of the drug-nanocarrier interactions. The results show that incorporating PEG onto GO nanosheets enhances adsorption energies and binding affinities for Favipiravir. Environmental factors and PEGylation influence the charge transfer and non-covalent interactions. PEGylation leads to faster Favipiravir release kinetics. Favorable thermodynamics are observed, especially in aqueous environments. Electronic properties, quantum descriptors, and theoretical spectra provide further insights into molecular interactions.

Publisher

Springer Science and Business Media LLC

Reference45 articles.

1. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection;Du YX;Clinical Pharmacology & Therapeutics,2020

2. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials;Hassanipour S;Scientific reports,2021

3. Evaluation of favipiravir in the treatment of COVID-19 based on the real-world;Deng W;Expert review of anti-infective therapy,2022

4. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model;Abdelnabi R;EBioMedicine,2021

5. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model;Driouich J-S;Nature Communications,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3